Obstetric outcomes after medroxyprogesterone acetate treatment for early stage endometrial cancer or atypical endometrial hyperplasia: a single hospital-based study-Reference-Cited by-同舟云学术

Obstetric outcomes after medroxyprogesterone acetate treatment for early stage endometrial cancer or atypical endometrial hyperplasia: a single hospital-based study

Published:2023-01-20 Issue:4 Volume:28 Page:587-591
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Oishi Maki,Kasuga Yoshifumi^ORCID,Fukuma Yuka,Hamuro Asuka,Tamai Junko,Tanaka Yuya,Hasegawa Keita,Yoshimura Takuma,Ikenoue Satoru,Ochiai Daigo,Yamagami Wataru,Tanaka Mamoru

Funder

JSPS KAKENHI

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

https://link.springer.com/content/pdf/10.1007/s10147-023-02297-y.pdf

Reference15 articles.

1. Yamagami W, Aoki D (2015) Annual report of the committee on gynecologic oncology, the japan society of obstetrics and gynecology. J Obstet Gynaecol Res 41:1861–1869

2. Gallos ID, Yap J, Rajkhowa M et al (2012) Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol 207:266.e1-266.12

3. Yamagami W, Susumu N, Makabe T et al (2018) Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility? J Gynecol Oncol 29:e21